CORRECTED-BUZZ-Aeterna Zentaris Inc: Selects Ergomed to conduct late-stage study

Thu Jun 25, 2015 8:39am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Corrects company name to "Aeterna" from "Aetena" in headline and text)

** Canadian drug developer's U.S.-listed shares up 7.4 pct at $0.29 pre-market

** UK-based drug developer Ergomed PLC will manage late-stage confirmatory study of Aeterna's drug Macrilen, used to evaluate growth hormone deficiency in adults

** Macimorelin, under the trade name Macrilen, has been granted orphan drug designation by the FDA for diagnosis of adult growth hormone deficiency

** Up to Wednesday's close, Aeterna's Toronto-listed stock had declined nearly 72 pct over the last 12 months